BETA


2017/0341(NLE) Subjecting the new psychoactive substance N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) to control measures

Progress: Procedure lapsed or withdrawn

Lead committee dossier:

Events

2018/02/28
   EP - Committee referral announced in Parliament
2018/02/08
   EC - Legislative proposal published
Details

PURPOSE: to subject the new psychoactive substance N-(1-amino-3-methyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) to control measures.

PROPOSED ACT: Council Implementing Decision.

ROLE OF THE EUROPEAN PARLIAMENT: the Council adopts the act after consulting the European Parliament but without being obliged to follow its opinion.

BACKGROUND: the risk assessment report on AB-CHMINACA prepared by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and sent to the Commission and the Council on 14 November 2017 concludes that this substance - available in the Union since at least April 2014 and detected in 24 Member States - is a synthetic cannabinoid with similar effects to those of THC, but with additional life-threatening toxicity. More than 4600 seizures have been made within the Union.

ADB-CHMINACA is typically sold in small and wholesale amounts in head shops, branded as a legal high as smoking mixtures or as powder, as well as on the internet, branded as a legal replacement for cannabis. It has no recognised human or veterinary medical use in the Union.

Three Member States have reported 31 deaths associated with ADB-CHMINACA. In addition, one Member State reported 7 acute non-fatal intoxications associated with the substance.

The available evidence and information on the health and social risks that the substance poses provides sufficient grounds for subjecting ADB-CHMINACA to control measures across the Union.

CONTENT: the draft Council decision aims to subject the new psychoactive substance AB-CHMINACA to the control measures and criminal penalties provided for by Member States legislation, in accordance with their obligations under the United Nations Single Convention on Narcotic Drugs of 1971.

For more details, see the summary of the Commission's initial legislative proposal dated 18.12.2017.

Documents
2018/02/06
   EP - Committee draft report
Documents
2017/12/18
   EP - Preparatory document
Details

PURPOSE: to subject the new psychoactive substance N-(1-amino-3-methyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) to control measures.

PROPOSED ACT: Council Implementing Decision.

ROLE OF THE EUROPEAN PARLIAMENT: the Council adopts the act after consulting the European Parliament but without being obliged to follow the opinion of the European Parliament.

BACKGROUND: on 15 September 2017, following the request made by the Commission and seven Member States and pursuant to Council Decision 2005/387/JHA on the information exchange, risk-assessment and control of new psychoactive substances, the Council requested an assessment of the risks caused by the use, manufacture and trafficking of the new psychoactive substance AB-CHMINACA , the involvement of organised crime and the possible consequences of control measures introduced on this substance.

A risk assessment report on the new psychoactive substance was drawn up by the Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), and was subsequently submitted to the Commission on 14 November 2017.

The main results of the risk assessment are the following:

AB-CHMINACA is a synthetic cannabinoid . It shows similar effects to THC, which is responsible for the major psychoactive effects of cannabis, but with additional life-threatening toxicity. It is typically sold in small and wholesale amounts branded as ‘legal high’ smoking mixtures and as powder in head shops as well as on the internet as ‘legal’ replacements for cannabis. It may also be sold directly on the illicit drug market; the substance has been available in the European Union since at least April 2014 and has been detected in 24 Member States. More than 4600 seizures have been made within the European Union. 31 deaths associated with ABCHMINACA have been reported by six Member States. Seven acute non-fatal intoxications associated with AB-CHMINACA were reported by four Member States.

This substance has no recognised human or veterinary medical use in the Union nor, it appears, elsewhere. There is no information on the involvement of organised crime.

The risk assessment report reveals that many of the questions related to AB-CHMINACA could be answered through further research. However, the available evidence and information on the health and social risks that the substance poses provides sufficient ground for subjecting AB-CHMINACA to control measures across the Union.

CONTENT: the purpose of this proposal for a Council Implementing Decision is to call upon the Member States to subject the new psychoactive substance AB-CHMINACA to control measures across the Union and criminal penalties as provided under their legislation by virtue of their obligations under the 1971 United Nations Single Convention on Narcotic Drugs.

Currently, 18 Member States control AB-CHMINACA under national drug control legislation and three Member States control it under other legislation.

Subjecting this substance to control measures across the Union would help avoid the emergence of obstacles in cross-border law enforcement and judicial cooperation, and would help protect from the risks that its availability and use can pose.

The United Kingdom shall not take part in the adoption of this Decision.

Documents

History

(these mark the time of scraping, not the official date of the change)

docs/0/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE618.024
New
https://www.europarl.europa.eu/doceo/document/LIBE-PR-618024_EN.html
events/2/type
Old
Committee referral announced in Parliament, 1st reading/single reading
New
Committee referral announced in Parliament
events/0
date
2017-12-18T00:00:00
type
Preparatory document
body
EP
docs
summary
events/0
date
2017-12-18T00:00:00
type
Initial legislative proposal published
body
EC
docs
summary
activities
  • date: 2017-12-18T00:00:00 docs: url: http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2017/0758/COM_COM(2017)0758_EN.pdf title: COM(2017)0758 type: Initial legislative proposal published celexid: CELEX:52017PC0758:EN body: EC commission: DG: url: http://ec.europa.eu/info/departments/migration-and-home-affairs_en title: Migration and Home Affairs Commissioner: AVRAMOPOULOS Dimitris type: Initial legislative proposal published
  • date: 2018-02-08T00:00:00 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=5390%2F18&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC type: Legislative proposal published title: 05390/2018 body: EC commission: DG: url: http://ec.europa.eu/info/departments/migration-and-home-affairs_en title: Migration and Home Affairs Commissioner: AVRAMOPOULOS Dimitris type: Legislative proposal published
  • date: 2018-02-28T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading
commission
  • body: EC dg: Migration and Home Affairs commissioner: AVRAMOPOULOS Dimitris
committees
    docs
    • date: 2018-02-06T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE618.024 title: PE618.024 type: Committee draft report body: EP
    events
    • date: 2017-12-18T00:00:00 type: Initial legislative proposal published body: EC docs: url: http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2017/0758/COM_COM(2017)0758_EN.pdf title: COM(2017)0758 url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2017&nu_doc=0758 title: EUR-Lex summary: PURPOSE: to subject the new psychoactive substance N-(1-amino-3-methyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) to control measures. PROPOSED ACT: Council Implementing Decision. ROLE OF THE EUROPEAN PARLIAMENT: the Council adopts the act after consulting the European Parliament but without being obliged to follow the opinion of the European Parliament. BACKGROUND: on 15 September 2017, following the request made by the Commission and seven Member States and pursuant to Council Decision 2005/387/JHA on the information exchange, risk-assessment and control of new psychoactive substances, the Council requested an assessment of the risks caused by the use, manufacture and trafficking of the new psychoactive substance AB-CHMINACA , the involvement of organised crime and the possible consequences of control measures introduced on this substance. A risk assessment report on the new psychoactive substance was drawn up by the Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), and was subsequently submitted to the Commission on 14 November 2017. The main results of the risk assessment are the following: AB-CHMINACA is a synthetic cannabinoid . It shows similar effects to THC, which is responsible for the major psychoactive effects of cannabis, but with additional life-threatening toxicity. It is typically sold in small and wholesale amounts branded as ‘legal high’ smoking mixtures and as powder in head shops as well as on the internet as ‘legal’ replacements for cannabis. It may also be sold directly on the illicit drug market; the substance has been available in the European Union since at least April 2014 and has been detected in 24 Member States. More than 4600 seizures have been made within the European Union. 31 deaths associated with ABCHMINACA have been reported by six Member States. Seven acute non-fatal intoxications associated with AB-CHMINACA were reported by four Member States. This substance has no recognised human or veterinary medical use in the Union nor, it appears, elsewhere. There is no information on the involvement of organised crime. The risk assessment report reveals that many of the questions related to AB-CHMINACA could be answered through further research. However, the available evidence and information on the health and social risks that the substance poses provides sufficient ground for subjecting AB-CHMINACA to control measures across the Union. CONTENT: the purpose of this proposal for a Council Implementing Decision is to call upon the Member States to subject the new psychoactive substance AB-CHMINACA to control measures across the Union and criminal penalties as provided under their legislation by virtue of their obligations under the 1971 United Nations Single Convention on Narcotic Drugs. Currently, 18 Member States control AB-CHMINACA under national drug control legislation and three Member States control it under other legislation. Subjecting this substance to control measures across the Union would help avoid the emergence of obstacles in cross-border law enforcement and judicial cooperation, and would help protect from the risks that its availability and use can pose. The United Kingdom shall not take part in the adoption of this Decision.
    • date: 2018-02-08T00:00:00 type: Legislative proposal published body: EC docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=5390%2F18&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC title: 05390/2018 summary: PURPOSE: to subject the new psychoactive substance N-(1-amino-3-methyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) to control measures. PROPOSED ACT: Council Implementing Decision. ROLE OF THE EUROPEAN PARLIAMENT: the Council adopts the act after consulting the European Parliament but without being obliged to follow its opinion. BACKGROUND: the risk assessment report on AB-CHMINACA prepared by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and sent to the Commission and the Council on 14 November 2017 concludes that this substance - available in the Union since at least April 2014 and detected in 24 Member States - is a synthetic cannabinoid with similar effects to those of THC, but with additional life-threatening toxicity. More than 4600 seizures have been made within the Union. ADB-CHMINACA is typically sold in small and wholesale amounts in head shops, branded as a legal high as smoking mixtures or as powder, as well as on the internet, branded as a legal replacement for cannabis. It has no recognised human or veterinary medical use in the Union. Three Member States have reported 31 deaths associated with ADB-CHMINACA. In addition, one Member State reported 7 acute non-fatal intoxications associated with the substance. The available evidence and information on the health and social risks that the substance poses provides sufficient grounds for subjecting ADB-CHMINACA to control measures across the Union. CONTENT: the draft Council decision aims to subject the new psychoactive substance AB-CHMINACA to the control measures and criminal penalties provided for by Member States legislation, in accordance with their obligations under the United Nations Single Convention on Narcotic Drugs of 1971. For more details, see the summary of the Commission's initial legislative proposal dated 18.12.2017.
    • date: 2018-02-28T00:00:00 type: Committee referral announced in Parliament, 1st reading/single reading body: EP
    links
    other
    • body: EC dg: url: http://ec.europa.eu/info/departments/migration-and-home-affairs_en title: Migration and Home Affairs commissioner: AVRAMOPOULOS Dimitris
    procedure/dossier_of_the_committee
    Old
    LIBE/8/11880
    New
    • LIBE/8/11880
    procedure/subject
    Old
    • 7.30.30.04 Action to combat drugs and drug-trafficking
    New
    7.30.30.04
    Action to combat drugs and drug-trafficking
    activities/0/docs/0/text
    • PURPOSE: to subject the new psychoactive substance N-(1-amino-3-methyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) to control measures.

      PROPOSED ACT: Council Implementing Decision.

      ROLE OF THE EUROPEAN PARLIAMENT: the Council adopts the act after consulting the European Parliament but without being obliged to follow the opinion of the European Parliament.

      BACKGROUND: on 15 September 2017, following the request made by the Commission and seven Member States and pursuant to Council Decision 2005/387/JHA on the information exchange, risk-assessment and control of new psychoactive substances, the Council requested an assessment of the risks caused by the use, manufacture and trafficking of the new psychoactive substance AB-CHMINACA, the involvement of organised crime and the possible consequences of control measures introduced on this substance.

      A risk assessment report on the new psychoactive substance was drawn up by the Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), and was subsequently submitted to the Commission on 14 November 2017.

      The main results of the risk assessment are the following:

      • AB-CHMINACA is a synthetic cannabinoid. It shows similar effects to THC, which is responsible for the major psychoactive effects of cannabis, but with additional life-threatening toxicity. It is typically sold in small and wholesale amounts branded as ‘legal high’ smoking mixtures and as powder in head shops as well as on the internet as ‘legal’ replacements for cannabis. It may also be sold directly on the illicit drug market;
      • the substance has been available in the European Union since at least April 2014 and has been detected in 24 Member States. More than 4600 seizures have been made within the European Union. 31 deaths associated with ABCHMINACA have been reported by six Member States. Seven acute non-fatal intoxications associated with AB-CHMINACA were reported by four Member States.

      This substance has no recognised human or veterinary medical use in the Union nor, it appears, elsewhere. There is no information on the involvement of organised crime.

      The risk assessment report reveals that many of the questions related to AB-CHMINACA could be answered through further research. However, the available evidence and information on the health and social risks that the substance poses provides sufficient ground for subjecting AB-CHMINACA to control measures across the Union.

      CONTENT: the purpose of this proposal for a Council Implementing Decision is to call upon the Member States to subject the new psychoactive substance AB-CHMINACA to control measures across the Union and criminal penalties as provided under their legislation by virtue of their obligations under the 1971 United Nations Single Convention on Narcotic Drugs.

      Currently, 18 Member States control AB-CHMINACA under national drug control legislation and three Member States control it under other legislation.

      Subjecting this substance to control measures across the Union would help avoid the emergence of obstacles in cross-border law enforcement and judicial cooperation, and would help protect from the risks that its availability and use can pose.

      The United Kingdom shall not take part in the adoption of this Decision.

    activities/0/docs/0/type
    Old
    Legislative proposal published
    New
    Initial legislative proposal published
    activities/0/type
    Old
    Legislative proposal published
    New
    Initial legislative proposal published
    activities/1
    date
    2018-02-08T00:00:00
    docs
    url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=5390%2F18&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC type: Legislative proposal published title: 05390/2018
    type
    Legislative proposal published
    body
    EC
    commission
    DG: url: http://ec.europa.eu/info/departments/migration-and-home-affairs_en title: Migration and Home Affairs Commissioner: AVRAMOPOULOS Dimitris
    activities/2
    date
    2018-02-28T00:00:00
    body
    EP
    type
    Committee referral announced in Parliament, 1st reading/single reading
    committees/0
    body
    EP
    responsible
    True
    committee_full
    Civil Liberties, Justice and Home Affairs
    committee
    LIBE
    procedure/dossier_of_the_committee
    LIBE/8/11880
    procedure/stage_reached
    Old
    Preparatory phase in Parliament
    New
    Procedure lapsed or withdrawn
    activities
    • date: 2017-12-18T00:00:00 docs: url: http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2017/0758/COM_COM(2017)0758_EN.pdf celexid: CELEX:52017PC0758:EN type: Legislative proposal published title: COM(2017)0758 type: Legislative proposal published body: EC commission: DG: url: http://ec.europa.eu/info/departments/migration-and-home-affairs_en title: Migration and Home Affairs Commissioner: AVRAMOPOULOS Dimitris
    committees
    • body: EP responsible: True committee_full: Civil Liberties, Justice and Home Affairs committee: LIBE
    links
    other
    • body: EC dg: url: http://ec.europa.eu/info/departments/migration-and-home-affairs_en title: Migration and Home Affairs commissioner: AVRAMOPOULOS Dimitris
    procedure
    reference
    2017/0341(NLE)
    title
    Subjecting the new psychoactive substance N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) to control measures
    stage_reached
    Preparatory phase in Parliament
    subtype
    Consent by Parliament
    type
    NLE - Non-legislative enactments
    subject
    7.30.30.04 Action to combat drugs and drug-trafficking